Individualizing NSAID therapy in axial spondyloarthritis: N-of-1 trials with Bayesian analysis.

ABSTRACT:

Objective

Axial spondyloarthritis (axSpA) is a chronic inflammatory disease predominantly affecting the spine and sacroiliac joints. NSAIDs are first-line therapy, but individual responses vary widely. We evaluated the efficacy and patient preference of three NSAIDs (celecoxib, meloxicam and naproxen) through Bayesian N-of-1 clinical trials to optimize axSpA management.

Methods

We conducted N-of-1 trials with 42 patients meeting ASAS criteria for axSpA. Each patient was asked to complete two cycles of randomized double-blind crossover comparisons of the three NSAIDs, each for 4 weeks. The primary end point was the change in the Ankylosing Spondylitis Disease Activity Score (ASDAS). Bayesian analysis assessed the average treatment effect of each NSAID based on individual pati

SUBMITTER: Hwang MC 

PROVIDER: S-EPMC12671866 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature